Law360, New York (September 02, 2009, 5:36 PM ET) -- A federal judge has refused to dismiss investor lawsuits accusing pharmaceutical giants Merck & Co. and Schering-Plough Corp. and several of their officers and directors of concealing clinical trial results that showed the anti-cholesterol drug Vytorin, jointly marketed by both companies, to be ineffective.
Judge Dennis M. Cavanaugh of the U.S. District Court for the District of New Jersey issued opinions Monday in the consolidated lawsuits against both companies finding that the plaintiffs had adequately pleaded claims under the Securities Act and Exchange Act, meeting the...
Vytorin Securities Suits Survive Dismissal Bids
To view the full article, take a free trial now.
